AnaptysBio Inc
ANAB
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.36B
Close$
$-14.56
131.2% downside
Current Fair Value
131.2% downsideOvervalued by 131.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.36 Billion |
|---|---|
| Enterprise Value | $1.50 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.46 |
| Beta | 0.41 |
| Outstanding Shares | 29,264,000 |
Return
| Return on Equity | 1849.06% |
|---|---|
| Return on Assets | 61.75% |
| Return on Invested Capital | 41.94% |
Valuation & Multiples
| P/E Ratio | 6.81 |
|---|---|
| PEG | -1.18 |
| Price to Sales | 5.83 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 6.3 |
| Enterprise Value to EBIT | 12.67 |
| Enterprise Value to Net Income | 7 |
| Total Debt to Enterprise | 0.18 |
| Debt to Equity | 25.47 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 23, 2026
EPS Estimate
$-0.47
Average shareholder expectationRevenue Estimate
$14.06 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$-1.84
Average shareholder expectationRevenue Estimate
$25.56 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 164.10% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.04%▼ 105.70% |
|---|---|
| Total Invested | $556,529▼ 99.97% |
| Investors Holding | 4▼ 217.00% |
ESG Score
No data
About AnaptysBio Inc
CEO: Hamza Suria